Puma Biotechnology, Inc.
Puma Biotechnology, Inc. logo
PBYI

Puma Biotechnology, Inc. (PBYI)

$4.43.93%

Market is closed
– opens on 8 PM, 12 Dec 2022
  • $

1D

1W

1M

1Y

3Y

5Y

Key Stats

$4.32
Day's Range
$4.569
$1.6
52-Week Range
$4.81
1 month return45.21%
3 month return62.36%
1 year return54.39%
5 year return95.65%

Company Information

Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and commercialization of innovative products to enhance cancer care. Puma in-licenses the global development and commercialization rights to PB272 (neratinib, oral), PB272 (neratinib, intravenous) and PB357. Neratinib, oral was approved by the U.S. Food and Drug Administration in 2017 for the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer, following adjuvant trastuzumab-based therapy, and is marketed in the United States as NERLYNX® (neratinib) tablets. In February 2020, NERLYNX was also approved by the FDA in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting. NERLYNX was granted marketing authorization by the European Commission in 2018 for the extended adjuvant treatment of adult patients with early stage hormone receptor-positive HER2-overexpressed/amplified breast cancer and who are less than one year from completion of prior adjuvant trastuzumab-based therapy. NERLYNX is a registered trademark of Puma Biotechnology, Inc.
OrganizationPuma Biotechnology, Inc.
Employees196
CEOMr. Alan H. Auerbach
IndustryHealth Technology

Analyst Recommendation

based on 7 analysts ratings

Sell
28%
Buy
14%
Hold
57%
Sell

Based on 7 Wall street analysts offering stock ratings for Puma Biotechnology, Inc.(by analysts ranked 0 to 5 stars)

Analyst Forecast

What analysts predicted

Upside of 22.73%

Current

$4.4

Target

$5.4

Recommendation Trend

Based on 7 analyst

Current1M Ago3M Ago
Buy
2
2
2
Hold
1
3
3
Sell
4
5
5
Consensus
SELL
SELL
SELL

Company Financials

  • Annual
  • Quarterly

Highlights

Market Capitalization
209.0M
Book Value
$0.49
Dividend Share
0.0
Dividend Yield
0.0%
Earnings Per Share (EPS)
0.22
PE Ratio
20.82
PEG Ratio
0.03
Wall Street Target Price
5.4

Valuation

Trailing PE20.82
Forward PE11.42
Price/Book (mrq)
9.17
Enterprise Value
240.0M
Enterprise Value/Revenue
1.1
Enterprise Value/Ebitda
7.94

Technicals

Beta
0.92
50 Day MA
3.02
200 Day MA
2.79

Institutional Holdings

Camber Capital Management LLC

9.28%

Vanguard Group Inc

7.94%

Millennium Management LLC

4.86%

Renaissance Technologies Corp

4.33%

BlackRock Inc

4.08%

Athyrium Capital Management LP

3.93%

Discover more

Frequently Asked Questions

What is Puma Biotechnology, Inc. share price today?

Can Indians buy Puma Biotechnology, Inc. shares?

How can I buy Puma Biotechnology, Inc. shares from India?

Can Fractional shares of Puma Biotechnology, Inc. be purchased?

What are the documents required to start investing in Puma Biotechnology, Inc. stocks?

What are today’s High and Low prices of Puma Biotechnology, Inc.?

What are today’s traded volumes of Puma Biotechnology, Inc.?

What is today’s market capitalisation of Puma Biotechnology, Inc.?

What is the 52 Week High and Low Range of Puma Biotechnology, Inc.?

How much percentage Puma Biotechnology, Inc. is down from its 52 Week High?

How much percentage Puma Biotechnology, Inc. is up from its 52 Week low?

What are the historical returns of Puma Biotechnology, Inc.?

Who is the Chief Executive Officer (CEO) of Puma Biotechnology, Inc.?

Trading and brokerage services provided by

Banking and Remittance services provided by

Technology services provided by : Finzoomers Services Private Limited

Disclaimer: These services are not for exchange traded products.The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Finzoomers Services Private Limited acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*